Is Ozempic Still the Best Weight-Loss Drug in 2026?

Ozempic is not the best weight-loss drug available in 2026 — it never really was, by design. It's a diabetes medication that happens to cause meaningful weight loss, and the landscape has moved well past it on both efficacy and indication.

What Ozempic Actually Is (and Isn't)

Ozempic is semaglutide at doses up to 2 mg weekly, FDA-approved for glycemic control in type 2 diabetes and cardiovascular risk reduction. The weight-loss formulation of the same molecule is Wegovy at 2.4 mg weekly — a distinct product with its own obesity indication. That distinction matters clinically: in the STEP-2 trial, published in NEJM, semaglutide 1.0 mg (the Ozempic maintenance dose) produced 7.0% mean weight loss versus 9.6% for the 2.4 mg obesity dose. [7] The gap is consistent and dose-dependent. Patients using Ozempic off-label for weight loss are getting a real effect — just not the maximum one.

The SELECT trial, also published in NEJM in 2023, gave semaglutide 2.4 mg a significant cardiovascular outcomes win: a 20% relative risk reduction in major cardiovascular events in people with obesity and established CVD but without diabetes. [4] That outcome data applies to Wegovy's dose, not Ozempic's, which reinforces the distinction when counseling patients.

For a deeper look at how the semaglutide family stacks up head-to-head, see our breakdown of compounded semaglutide vs brand-name Wegovy.

Tirzepatide Has Moved the Goalposts

Tirzepatide — sold as Zepbound for obesity and Mounjaro for diabetes — is now the highest-efficacy approved weight-loss drug in the United States. SURMOUNT-1, published in NEJM, showed mean weight loss of 20.9% at 72 weeks on the 15 mg dose versus 3.1% for placebo. [5] Systematic reviews place tirzepatide roughly 4–5 percentage points ahead of semaglutide 2.4 mg at equivalent follow-up — a clinically meaningful gap, not a rounding error. [6]

Zepbound received FDA approval for obesity in late 2023, and a second indication for moderate-to-severe obstructive sleep apnea in adults with obesity followed in 2024. [3] No comparable second-indication expansion has occurred for Wegovy or Ozempic at this writing. For a full efficacy and tolerability comparison, our article on tirzepatide vs semaglutide for men's fat loss in 2026 covers the head-to-head data in detail.

If you're ready to explore which agent fits your profile, compare current GLP-1 prescribing providers or get started with a structured weight management program that matches drug selection to your metabolic history.

The Honest Bottom Line on Ozempic

Ozempic still belongs in clinical practice — specifically for patients managing type 2 diabetes who also benefit from weight loss, where it performs well and carries strong outcomes data. What it is not is the default best choice for someone whose primary goal is weight reduction. Wegovy is the correct semaglutide product for that indication, and Zepbound outperforms it on mean weight loss in trials. The question "is Ozempic the best?" conflates a diabetes drug's off-label reputation with the actual evidence hierarchy.

For patients who want the highest-efficacy approved option in 2026, tirzepatide wins on the numbers. For patients with type 2 diabetes and cardiovascular disease, semaglutide at the Ozempic dose still has robust outcome data justifying its use. Those are different patients with different goals, and the answer changes accordingly. If you want a clinician to sort through which option fits your profile, Shed offers GLP-1 prescribing with drug selection guided by metabolic workup rather than brand familiarity.

---

Frequently asked questions

Is Ozempic approved for weight loss?

Ozempic is not FDA-approved for weight loss; it is approved for type 2 diabetes management and cardiovascular risk reduction in diabetic patients. The semaglutide product specifically approved for chronic weight management is Wegovy at 2.4 mg weekly, which has its own obesity indication supported by the STEP trial program published in NEJM.

How does Ozempic compare to Zepbound for weight loss?

Zepbound (tirzepatide) produces greater average weight loss than either Ozempic or Wegovy in clinical trials. SURMOUNT-1 showed nearly 21% mean weight loss on tirzepatide 15 mg at 72 weeks; Wegovy's STEP-1 data showed approximately 15–17% at 68 weeks. Ozempic at its approved diabetes doses trails both. For most patients whose primary goal is weight reduction, tirzepatide is the stronger pharmacologic option based on current evidence.

What is the strongest weight-loss drug approved in 2026?

Tirzepatide (Zepbound) is the highest-efficacy FDA-approved weight-loss drug as of 2026, based on phase 3 SURMOUNT trial data published in NEJM. Investigational agents like retatrutide showed even larger reductions in early trial data but remain pending full approval. Among approved options, Zepbound at 10–15 mg outperforms semaglutide 2.4 mg by approximately 4–5 percentage points in mean body-weight reduction.